Jeff Bezos Backed Grail Before It Lost Half Its Value. Here's Whether He Was Early -- or Just Wrong.

The fate of Grail's stock will ultimately be decided in the cost-benefit calculations of medical insurers.

Inhibiting protein to treat myeloproliferative neoplasms shows preclinical promise

Inhibiting menin, a protein that supports leukemia growth and is already targeted to treat some forms of leukemia, also holds ...